NCT04648475 2023-04-18
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
Clinical Trials
3 trialsNCT04649983 2023-04-18
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05651100 2022-12-14
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Kecellitics Biotech Company Ltd
Phase 1/2 Unknown